APOLD1 loss causes endothelial dysfunction involving cell junctions, cytoskeletal architecture, and Weibel-Palade bodies, while disrupting hemostasis.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 03 2023
Historique:
received: 27 05 2022
pubmed: 1 6 2022
medline: 3 3 2023
entrez: 31 5 2022
Statut: epublish

Résumé

Vascular homeostasis is impaired in various diseases thereby contributing to the progression of their underlying pathologies. The endothelial immediate early gene Apolipoprotein L domain-containing 1 (APOLD1) helps to regulate endothelial function. However, its precise role in endothelial cell biology remains unclear. We have localized APOLD1 to endothelial cell contacts and to Weibel-Palade bodies (WPB) where it associates with von Willebrand factor (VWF) tubules. Silencing of APOLD1 in primary human endothelial cells disrupted the cell junction-cytoskeletal interface, thereby altering endothelial permeability accompanied by spontaneous release of WPB contents. This resulted in an increased presence of WPB cargoes, notably VWF and angiopoietin-2 in the extracellular medium. Autophagy flux, previously recognized as an essential mechanism for the regulated release of WPB, was impaired in the absence of APOLD1. In addition, we report APOLD1 as a candidate gene for a novel inherited bleeding disorder across three generations of a large family in which an atypical bleeding diathesis was associated with episodic impaired microcirculation. A dominant heterozygous nonsense APOLD1:p.R49* variant segregated to affected family members. Compromised vascular integrity resulting from an excess of plasma angiopoietin-2, and locally impaired availability of VWF may explain the unusual clinical profile of APOLD1:p.R49* patients. In summary, our findings identify APOLD1 as an important regulator of vascular homeostasis and raise the need to consider testing of endothelial cell function in patients with inherited bleeding disorders without apparent platelet or coagulation defects.

Identifiants

pubmed: 35638551
doi: 10.3324/haematol.2022.280816
pmc: PMC9973481
doi:

Substances chimiques

von Willebrand Factor 0
Angiopoietin-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

772-784

Commentaires et corrections

Type : CommentIn

Références

Mediterr J Hematol Infect Dis. 2013 Jul 10;5(1):e2013046
pubmed: 23936617
Blood. 2019 Jan 17;133(3):193-204
pubmed: 30442679
Int J Mol Sci. 2019 Aug 24;20(17):
pubmed: 31450612
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6467-E6476
pubmed: 29941602
Nat Rev Mol Cell Biol. 2009 Jan;10(1):21-33
pubmed: 19197329
Nat Commun. 2015 Jan 30;6:5962
pubmed: 25635707
Exp Physiol. 2010 Nov;95(11):1071-80
pubmed: 20696783
Sci Rep. 2016 Jun 30;6:29003
pubmed: 27357373
Blood. 2004 Jun 1;103(11):4150-6
pubmed: 14976056
Nat Commun. 2016 Mar 29;7:11097
pubmed: 27020697
Brain Res Bull. 2013 Sep;98:111-21
pubmed: 23973431
J Clin Invest. 2012 Jun;122(6):1991-2005
pubmed: 22585576
J Recept Signal Transduct Res. 2019 Jun;39(3):187-193
pubmed: 31429357
J Cell Biol. 2012 Aug 20;198(4):481-9
pubmed: 22908306
Genet Mol Res. 2013 Oct 07;12(4):4162-70
pubmed: 24114211
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Circulation. 2008 Mar 18;117(11):1449-59
pubmed: 18347221
Cell. 2020 Feb 20;180(4):764-779.e20
pubmed: 32059779
Nat Commun. 2018 Apr 17;9(1):1511
pubmed: 29666442
Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a002998
pubmed: 20066121
Hum Mutat. 2020 Jan;41(1):277-290
pubmed: 31562665
Biochemistry (Mosc). 2002 Jan;67(1):75-84
pubmed: 11841342
EMBO J. 2001 Sep 3;20(17):4639-47
pubmed: 11532928
Haemophilia. 2016 Jul;22 Suppl 5:54-9
pubmed: 27405677
Haematologica. 2018 Jan;103(1):6-8
pubmed: 29290630
Nat Med. 2013 Oct;19(10):1281-7
pubmed: 24056772
J Cell Sci. 2005 Jan 15;118(Pt 2):291-300
pubmed: 15615773
J Neurosci. 2004 Apr 21;24(16):4092-103
pubmed: 15102925
J Mol Med (Berl). 2009 Jun;87(6):571-82
pubmed: 19337719
J Exp Med. 2015 Dec 14;212(13):2267-87
pubmed: 26642851
Eur J Clin Invest. 2020 Feb;50(2):e13191
pubmed: 31797367
Cell Rep. 2014 Oct 23;9(2):504-13
pubmed: 25373898
Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1825-34
pubmed: 10446060
Blood. 2013 Apr 4;121(14):2773-84
pubmed: 23355534
Haematologica. 2018 Jan;103(1):148-162
pubmed: 28983057
Hemasphere. 2019 Sep 27;3(5):e297
pubmed: 31942548
Nat Rev Drug Discov. 2017 Sep;16(9):635-661
pubmed: 28529319
Blood. 1985 Sep;66(3):710-3
pubmed: 3875375
Int J Biochem Cell Biol. 2021 Feb;131:105900
pubmed: 33301925
Neuropsychopharmacol Rep. 2021 Dec;41(4):485-495
pubmed: 34529365
Trends Mol Med. 2021 Apr;27(4):314-331
pubmed: 33309601
Blood. 2008 May 15;111(10):4958-64
pubmed: 18256319
FEBS J. 2022 Nov;289(22):6863-6870
pubmed: 35246944
Autophagy. 2019 Oct;15(10):1682-1693
pubmed: 30894055
Circ Res. 2017 Feb 3;120(3):449-471
pubmed: 28154097
Exp Transl Stroke Med. 2012 Jun 08;4(1):12
pubmed: 22681709
Int J Lab Hematol. 2018 May;40 Suppl 1:89-96
pubmed: 29741246
Blood. 2018 Jul 12;132(2):132-140
pubmed: 29866817
Hum Mol Genet. 2015 Feb 15;24(4):1142-54
pubmed: 25312062
J Cell Sci. 2008 Jan 1;121(Pt 1):19-27
pubmed: 18096688
Nat Commun. 2016 Aug 12;7:12471
pubmed: 27514992
Res Pract Thromb Haemost. 2019 Aug 01;3(4):718-732
pubmed: 31624792

Auteurs

Simon Stritt (S)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.

Paquita Nurden (P)

Institut de Rythmologie et de Modélisation Cardiaque, Hôpital Xavier Arnozan, Pessac, France. paquita.nurden@gmail.com.

Alan T Nurden (AT)

Institut de Rythmologie et de Modélisation Cardiaque, Hôpital Xavier Arnozan, Pessac, France.

Jean-François Schved (JF)

Department of Biological Hematology, CHU Montpellier, Université de Montpellier, Montpellier.

Jean-Claude Bordet (JC)

Hematology, Hospices civils de Lyon, Bron biology center and Hemostasis- Thrombosis, Lyon-1 University, Lyon.

Maguelonne Roux (M)

Laboratory of Excellence GENMED (Medical Genomics), Paris.

Marie-Christine Alessi (MC)

Aix Marseille University, INSERM, INRAE, C2VN, Marseille.

David-Alexandre Trégouët (DA)

Laboratory of Excellence GENMED (Medical Genomics), Paris; University of Bordeaux, INSERM, Bordeaux Population Health Research Center, U1219, Bordeaux.

Taija Mäkinen (T)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Muriel Giansily-Blaizot (M)

Department of Biological Hematology, CHU Montpellier, Université de Montpellier, Montpellier.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH